CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza ®) + RVD (Lenalidomide {Revlimid ®} + Bortezomib {Velcade ®} + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01038388
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:25.335125+00:00
Published At: 2021-11-03T00:00:00+00:00
Record Updated At: 2021-11-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-11-03"
protocolSection.identificationModule.nctId: "NCT01038388"
protocolSection.identificationModule.officialTitle: "A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza \u00ae) + RVD (Lenalidomide {Revlimid \u00ae} + Bortezomib {Velcade \u00ae} + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.